1.1M XNYS Volume
XNYS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 30.73 per share. | 04 Mar 2025 | 3,400 | 76,570 | - | 30.7 | 104,469 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 30.73 per share. | 04 Mar 2025 | 3,400 | 24,452 | - | 30.7 | 104,469 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 30.39 per share. | 04 Mar 2025 | 25,000 | 2,320,571 | - | 30.4 | 759,648 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 30.73 per share. | 04 Mar 2025 | 900 | 25,291 | - | 30.7 | 27,653 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2025 | 3,750 | 99,719 | - | 0 | Common Shares | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2025 | 3,750 | 11,250 | - | - | Restricted Share Unit Award | |
| Kimberly Gentile | SVP, Clinical Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2025 | 15,000 | 15,000 | - | - | Restricted Share Unit Award | |
| Kimberly Gentile | SVP, Clinical Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2025 | 91,000 | 91,000 | - | - | Stock Options (Right to buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.64 per share. | 05 Jan 2025 | 1,956 | 97,763 | - | 38.6 | 75,580 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2025 | 343,000 | 343,000 | - | - | Stock Options (Right to buy) | |
| Vlad Coric | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2025 | 57,000 | 57,000 | - | - | Restricted Share Unit Award | |
| Vlad Coric | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2025 | 14,250 | 42,750 | - | - | Restricted Share Unit Award | |
| Vlad Coric | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2025 | 14,250 | 1,803,409 | - | 0 | Common Shares | |
| Vlad Coric | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.64 per share. | 05 Jan 2025 | 6,805 | 1,796,604 | - | 38.6 | 262,945 | Common Shares |
| Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2025 | 4,750 | 14,250 | - | - | Restricted Share Unit Award | |
| Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2025 | 4,750 | 7,133 | - | 0 | Common Shares | |
| Bruce Car | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.64 per share. | 05 Jan 2025 | 2,331 | 4,802 | - | 38.6 | 90,070 | Common Shares |
| Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2025 | 112,000 | 112,000 | - | - | Stock Options (Right to buy) | |
| Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2025 | 19,000 | 19,000 | - | - | Restricted Share Unit Award | |
| George C. Clark | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2025 | 2,500 | 66,168 | - | 0 | Common Shares | |
| George C. Clark | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.64 per share. | 05 Jan 2025 | 1,117 | 65,051 | - | 38.6 | 43,161 | Common Shares |
| George C. Clark | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2025 | 30,000 | 30,000 | - | - | Stock Options (Right to buy) | |
| George C. Clark | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2025 | 10,000 | 10,000 | - | - | Restricted Share Unit Award | |
| George C. Clark | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2025 | 2,500 | 7,500 | - | - | Restricted Share Unit Award | |
| Matthew Buten | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2025 | 4,250 | 12,750 | - | - | Restricted Share Unit Award | |
| Matthew Buten | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2025 | 17,000 | 17,000 | - | - | Restricted Share Unit Award | |
| Matthew Buten | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2025 | 104,000 | 104,000 | - | - | Stock Options (Right to buy) | |
| Matthew Buten | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.64 per share. | 05 Jan 2025 | 2,561 | 193,452 | - | 38.6 | 98,957 | Common Shares |
| Matthew Buten | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2025 | 4,250 | 196,013 | - | 0 | Common Shares | |
| Childs John W. | Director | Purchase of securities on an exchange or from another person at price $ 35.94 per share. | 30 Dec 2024 | 29,000 | 2,368,741 | - | 35.9 | 1,042,393 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 47.50 per share. | 02 Oct 2024 | 21,052 | 21,052 | - | 47.5 | 999,970 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 47.50 per share. | 02 Oct 2024 | 21,052 | 861,942 | - | 47.5 | 999,970 | Common Shares |
| Gregory Hugh Bailey | Director | Purchase of securities on an exchange or from another person at price $ 44.19 per share. | 24 Sep 2024 | 5,000 | 1,620,071 | - | 44.2 | 220,966 | Common Shares |
| W. Childs John | Director | Purchase of securities on an exchange or from another person at price $ 35.67 per share. | 18 Jul 2024 | 28,400 | 2,339,741 | - | 35.7 | 1,012,983 | Common Shares |
| Bruce Car | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 33.58 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | 33.6 | 1,007,490 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 35.58 per share. | 30 May 2024 | 28,000 | 2,311,341 | - | 35.6 | 996,240 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 35.17 per share. | 13 May 2024 | 28,500 | 2,283,341 | - | 35.2 | 1,002,470 | Common Shares |
| Gregory Hugh Bailey | Director | Purchase of securities on an exchange or from another person at price $ 34.19 per share. | 13 May 2024 | 15,000 | 1,615,071 | - | 34.2 | 512,877 | Common Shares |
| Julia P. Gregory | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 16,592 | 16,592 | - | - | Stock Option (Right to Buy) | |
| Gregory Hugh Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 16,592 | 16,592 | - | - | Stock Option (Right to Buy) | |
| Robert J. Hugin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 16,592 | 16,592 | - | - | Stock Option (Right to Buy) | |
| Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 16,592 | 16,592 | - | - | Stock Option (Right to Buy) | |
| John W. Childs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 16,592 | 16,592 | - | - | Stock Option (Right to Buy) | |
| Kishan Mehta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 16,592 | 16,592 | - | - | Stock Option (Right to Buy) | |
| Irina Antonijevic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 16,592 | 16,592 | - | - | Stock Option (Right to Buy) | |
| Gregory Hugh Bailey | Director | Purchase of securities on an exchange or from another person at price $ 39.18 per share. | 24 Apr 2024 | 25,503 | 1,600,071 | - | 39.2 | 999,169 | Common Shares |
| Gregory Hugh Bailey | Director | Purchase of securities on an exchange or from another person at price $ 41.00 per share. | 22 Apr 2024 | 48,780 | 1,574,568 | - | 41 | 1,999,980 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 41.00 per share. | 22 Apr 2024 | 24,391 | 24,391 | - | 41 | 1,000,031 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 41.00 per share. | 22 Apr 2024 | 97,560 | 4,096,512 | - | 41 | 3,999,960 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 41.00 per share. | 22 Apr 2024 | 73,170 | 2,254,841 | - | 41 | 2,999,970 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 41.00 per share. | 22 Apr 2024 | 121,951 | 1,788,417 | - | 41 | 4,999,991 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 41.00 per share. | 22 Apr 2024 | 73,170 | 73,170 | - | 41 | 2,999,970 | Common Shares |
| John W. Childs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 2,091 | 2,181,671 | - | - | Common Shares | |
| Vlad Coric | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 232 | 1,666,466 | - | - | Common Shares | |
| Vlad Coric | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 231 | 407,213 | - | - | Common Shares | |
| Vlad Coric | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 231 | 840,890 | - | - | Common Shares | |
| John W. Childs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 19,412 | 2,179,580 | - | - | Common Shares | |
| Vlad Coric | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 2,155 | 840,659 | - | - | Common Shares | |
| Vlad Coric | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 2,162 | 1,666,234 | - | - | Common Shares | |
| Vlad Coric | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 2,155 | 406,982 | - | - | Common Shares | |
| Coric Vlad | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2024 | 5,384 | 404,827 | - | - | Common Shares | |
| Vlad Coric | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2024 | 5,400 | 1,662,431 | - | - | Common Shares | |
| Coric Vlad | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2024 | 5,384 | 838,504 | - | - | Common Shares | |
| John W. Childs | Director | Other type of transaction at price $ 0.00 per share. | 08 Jan 2024 | 48,505 | 2,160,168 | - | - | Common Shares | |
| Gentile Kimberly | SVP, Clinical Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 96,250 | 96,250 | - | - | Stock Options (Right to buy) | |
| Buten Matthew | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 96,250 | 96,250 | - | - | Stock Options (Right to buy) | |
| Coric Vlad | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 275,000 | 275,000 | - | - | Stock Options (Right to buy) | |
| Car Bruce | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 96,250 | 96,250 | - | - | Stock Options (Right to buy) | |
| George Clark C. | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 27,500 | 27,500 | - | - | Stock Options (Right to buy) | |
| Antonijevic Irina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2023 | 11,000 | 114,000 | - | - | Stock Options (Right to Buy) | |
| Antonijevic Irina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2023 | 11,000 | 13,535 | - | 0 | Common Shares | |
| Antonijevic Irina | Director | Sale of securities on an exchange or to another person at price $ 41.79 per share. | 29 Dec 2023 | 11,000 | 2,535 | - | 41.8 | 459,663 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2023 | 78,750 | 78,750 | - | - | Stock Options (Right to buy) | |
| Vlad Coric | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2023 | 225,000 | 225,000 | - | - | Stock Options (Right to buy) | |
| Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2023 | 78,750 | 78,750 | - | - | Stock Options (Right to buy) | |
| George C. Clark | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2023 | 22,500 | 22,500 | - | - | Stock Options (Right to buy) | |
| Matthew Buten | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2023 | 78,750 | 78,750 | - | - | Stock Options (Right to buy) | |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 22.00 per share. | 05 Oct 2023 | 318,000 | 3,998,952 | - | 22 | 6,996,000 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 22.00 per share. | 05 Oct 2023 | 136,545 | 2,111,663 | - | 22 | 3,003,990 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 22.00 per share. | 05 Oct 2023 | 113,637 | 1,657,031 | - | 22 | 2,500,014 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 22.00 per share. | 05 Oct 2023 | 340,908 | 833,120 | - | 22 | 7,499,976 | Common Share |
| Matthew Buten | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 22.00 per share. | 05 Oct 2023 | 22,727 | 189,380 | - | 22 | 499,994 | Common Shares |
| Gregory Hugh Bailey | Director | Purchase of securities on an exchange or from another person at price $ 22.57 per share. | 04 Oct 2023 | 17,817 | 1,525,788 | - | 22.6 | 402,094 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 18.44 per share. | 30 Aug 2023 | 50,000 | 1,975,118 | - | 18.4 | 922,180 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 19.78 per share. | 04 Aug 2023 | 100,000 | 1,925,118 | - | 19.8 | 1,978,430 | Common Shares |
| Julia P. Gregory | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 52,906 | 52,906 | - | - | Stock Option (Right to Buy) | |
| Gregory Hugh Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 52,906 | 52,906 | - | - | Stock Option (Right to Buy) | |
| Robert J. Hugin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 52,906 | 52,906 | - | - | Stock Option (Right to Buy) | |
| Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 52,906 | 52,906 | - | - | Stock Option (Right to Buy) | |
| John W. Childs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 52,906 | 52,906 | - | - | Stock Option (Right to Buy) | |
| Kishan Mehta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 52,906 | 52,906 | - | - | Stock Option (Right to Buy) | |
| Irina Antonijevic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 52,906 | 52,906 | - | - | Stock Option (Right to Buy) | |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 15.97 per share. | 31 Oct 2022 | 25,800 | 1,543,394 | - | 16.0 | 411,995 | Common Stock |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 14.87 per share. | 28 Oct 2022 | 41,930 | 1,517,594 | - | 14.9 | 623,352 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 14.82 per share. | 28 Oct 2022 | 100,000 | 109,565 | - | 14.8 | 1,482,420 | Common Shares |
| Julia P. Gregory | Director | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 25 Oct 2022 | 9,523 | 25,665 | - | 10.5 | 99,992 | Common Shares |
| Gregory Hugh Bailey | Director | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 25 Oct 2022 | 200,000 | 1,507,971 | - | 10.5 | 2,100,000 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 25 Oct 2022 | 2,380,952 | 3,680,952 | - | 10.5 | 24,999,996 | Common Shares |
| John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 25 Oct 2022 | 1,328,867 | 1,825,118 | - | 10.5 | 13,953,104 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 25 Oct 2022 | 853,380 | 1,475,664 | - | 10.5 | 8,960,490 | Common Shares |
| Matthew Buten | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 25 Oct 2022 | 142,857 | 166,653 | - | 10.5 | 1,499,999 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 11.79 per share. | 05 Oct 2022 | 52,523 | 397,343 | - | 11.8 | 619,162 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 8.82 per share. | 05 Oct 2022 | 73,331 | 322,461 | - | 8.8 | 647,029 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 9.90 per share. | 05 Oct 2022 | 34,515 | 356,976 | - | 9.9 | 341,843 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 10.83 per share. | 05 Oct 2022 | 80,907 | 437,883 | - | 10.8 | 875,843 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 11.83 per share. | 05 Oct 2022 | 54,329 | 492,212 | - | 11.8 | 642,614 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 8.82 per share. | 05 Oct 2022 | 73,005 | 229,755 | - | 8.8 | 644,130 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 9.89 per share. | 05 Oct 2022 | 34,459 | 264,214 | - | 9.9 | 340,968 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 10.82 per share. | 05 Oct 2022 | 80,606 | 344,820 | - | 10.8 | 871,907 | Common Shares |
| Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 12.35 per share. | 05 Oct 2022 | 2,100 | 399,443 | - | 12.3 | 25,928 | Common Shares |
| Julia P. Gregory | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 4,119 | 0 | - | - | Stock Options (Right to Buy) | |
| Julia P. Gregory | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.84 per share. | 03 Oct 2022 | 4,119 | 4,119 | - | 4.8 | 19,936 | Common Shares |
| Julia P. Gregory | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.56 per share. | 03 Oct 2022 | 5,998 | 10,117 | - | 3.6 | 21,353 | Common Shares |
| Julia P. Gregory | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 03 Oct 2022 | 9,000 | 19,117 | - | 2.3 | 20,970 | Common Shares |
| Julia P. Gregory | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.06 per share. | 03 Oct 2022 | 9,000 | 28,117 | - | 3.1 | 27,540 | Common Shares |
| Julia P. Gregory | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.50 per share. | 03 Oct 2022 | 11,975 | 16,142 | - | 7.5 | 89,813 | Common Shares |
| Julia P. Gregory | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 4,119 | 4,119 | - | - | Stock Options (Right to Buy) | |
| Julia P. Gregory | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 5,998 | 5,998 | - | - | Stock Options (Right to Buy) | |
| Julia P. Gregory | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 9,000 | 9,000 | - | - | Stock Options (Right to Buy) | |
| Julia P. Gregory | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 9,000 | 9,000 | - | - | Stock Options (Right to Buy) | |
| Julia P. Gregory | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 5,998 | 0 | - | - | Stock Options (Right to Buy) | |
| Julia P. Gregory | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 9,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Julia P. Gregory | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 9,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Julia P. Gregory | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 125,000 | 125,000 | - | - | Stock Options (Right to buy) | |
| Gregory Hugh Bailey | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.50 per share. | 03 Oct 2022 | 11,975 | 1,307,971 | - | 7.5 | 89,813 | Common Shares |
| Gregory Hugh Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 03 Oct 2022 | 9,000 | 1,310,946 | - | 2.3 | 20,970 | Common Shares |
| Gregory Hugh Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.56 per share. | 03 Oct 2022 | 5,998 | 1,301,946 | - | 3.6 | 21,353 | Common Shares |
| Gregory Hugh Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.84 per share. | 03 Oct 2022 | 4,119 | 1,295,948 | - | 4.8 | 19,936 | Common Shares |
| Gregory Hugh Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 9,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Gregory Hugh Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 125,000 | 125,000 | - | - | Stock Options (Right to Buy) | |
| Gregory Hugh Bailey | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 4,119 | 4,119 | - | - | Stock Options (Right to Buy) | |
| Gregory Hugh Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.06 per share. | 03 Oct 2022 | 9,000 | 1,319,946 | - | 3.1 | 27,540 | Common Shares |
| Gregory Hugh Bailey | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 1,291,829 | 1,291,829 | - | 0 | Common Shares | |
| Gregory Hugh Bailey | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 5,998 | 5,998 | - | - | Stock Options (Right to Buy) | |
| Gregory Hugh Bailey | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 9,000 | 9,000 | - | - | Stock Options (Right to Buy) | |
| Gregory Hugh Bailey | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 9,000 | 9,000 | - | - | Stock Options (Right to Buy) | |
| Gregory Hugh Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 4,119 | 0 | - | - | Stock Options (Right to buy) | |
| Gregory Hugh Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 5,998 | 0 | - | - | Stock Options (Right to buy) | |
| Gregory Hugh Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 9,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Robert J. Hugin | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.50 per share. | 03 Oct 2022 | 12,959 | 12,959 | - | 7.5 | 97,193 | Common Shares |
| Michael T. Heffernan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.50 per share. | 03 Oct 2022 | 9,699 | 15,178 | - | 7.5 | 72,743 | Common Shares |
| John W. Childs | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 1,512,500 | 1,517,110 | - | 0 | Common Shares | |
| John W. Childs | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 5,000 | 5,000 | - | 0 | Common Shares | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 5,826 | 5,826 | - | 0 | Common Shares | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 6,500 | 12,326 | - | 0 | Common Shares | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 3,750 | 16,076 | - | 0 | Common Shares | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 1,875 | 17,951 | - | 0 | Common Shares | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.37 per share. | 03 Oct 2022 | 387 | 18,338 | - | 6.4 | 2,465 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.37 per share. | 03 Oct 2022 | 12,612 | 30,950 | - | 6.4 | 80,338 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.13 per share. | 03 Oct 2022 | 1,199 | 32,149 | - | 4.1 | 4,952 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.13 per share. | 03 Oct 2022 | 13,801 | 45,950 | - | 4.1 | 56,998 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.84 per share. | 03 Oct 2022 | 14,000 | 59,950 | - | 2.8 | 39,760 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.52 per share. | 03 Oct 2022 | 3,000 | 62,950 | - | 2.5 | 7,560 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.61 per share. | 03 Oct 2022 | 30,958 | 93,908 | - | 1.6 | 49,842 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.61 per share. | 03 Oct 2022 | 1,542 | 95,450 | - | 1.6 | 2,483 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 03 Oct 2022 | 295 | 95,745 | - | 1.0 | 304 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 03 Oct 2022 | 20,716 | 116,461 | - | 1.0 | 21,337 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.86 per share. | 03 Oct 2022 | 4,500 | 120,961 | - | 1.9 | 8,370 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 03 Oct 2022 | 12,500 | 133,461 | - | 0.5 | 6,750 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.00 per share. | 03 Oct 2022 | 37,492 | 95,969 | - | 7 | 262,444 | Common Shares |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 387 | 387 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 12,612 | 12,612 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 1,199 | 1,199 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 13,801 | 13,801 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 14,000 | 14,000 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 3,000 | 3,000 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 30,958 | 30,958 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 1,542 | 1,542 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 295 | 295 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 20,716 | 20,716 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 4,500 | 4,500 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 12,500 | 12,500 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 387 | 0 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 12,612 | 0 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 1,199 | 0 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 13,801 | 0 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 14,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 3,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 30,958 | 0 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 1,542 | 0 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 295 | 0 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 20,716 | 0 | - | - | Stock Options (Right to Buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 4,500 | 0 | - | - | Stock Options (Right to buy) | |
| Kimberly Gentile | SVP, Clinical Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 300,000 | 300,000 | - | - | Stock Options (Right to buy) | |
| Vlad Coric | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 46,025 | 622,284 | - | 0 | Common Shares | |
| Vlad Coric | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 249,130 | 249,130 | - | 0 | Common Shares | |
| Vlad Coric | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 156,750 | 156,750 | - | 0 | Common Shares | |
| Vlad Coric | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 9,565 | 9,565 | - | 0 | Common Shares | |
| Kishan Mehta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 125,000 | 125,000 | - | - | Stock Options (Right to buy) | |
| Kishan Mehta | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 5,320 | 5,320 | - | 0 | Common Shares | |
| Kishan Mehta | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 937 | 6,257 | - | 0 | Common Shares | |
| Kishan Mehta | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.84 per share. | 03 Oct 2022 | 4,119 | 10,376 | - | 4.8 | 19,936 | Common Shares |
| Kishan Mehta | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 6,502 | 6,502 | - | - | Stock Options (Right to Buy) | |
| Kishan Mehta | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.58 per share. | 03 Oct 2022 | 7,500 | 24,378 | - | 2.6 | 19,350 | Common Shares |
| Kishan Mehta | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.86 per share. | 03 Oct 2022 | 10,000 | 34,378 | - | 1.9 | 18,600 | Common Shares |
| Kishan Mehta | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.00 per share. | 03 Oct 2022 | 11,716 | 22,662 | - | 7 | 82,012 | Common Shares |
| Kishan Mehta | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 4,119 | 4,119 | - | - | Stock Options (Right to Buy) | |
| Kishan Mehta | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 10,000 | 10,000 | - | - | Stock Options (Right to Buy) | |
| Kishan Mehta | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 7,500 | 7,500 | - | - | Stock Options (Right to Buy) | |
| Kishan Mehta | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.61 per share. | 03 Oct 2022 | 6,502 | 16,878 | - | 4.6 | 29,974 | Common Shares |
| Kishan Mehta | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 4,119 | 0 | - | - | Stock Options (Right to Buy) | |
| Kishan Mehta | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 6,502 | 0 | - | - | Stock Options (Right to Buy) | |
| Kishan Mehta | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 7,500 | 0 | - | - | Stock Options (Right to Buy) | |
| Kishan Mehta | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 10,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Matthew Buten | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 11,450 | 0 | - | - | Stock Options (Right to Buy) | |
| Matthew Buten | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 300,000 | 300,000 | - | - | Stock Options (Right to Buy) | |
| Matthew Buten | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 1,550 | 0 | - | - | Stock Options (Right to Buy) | |
| Matthew Buten | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 11,450 | 11,450 | - | - | Stock Options (Right to Buy) | |
| Matthew Buten | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 1,550 | 1,550 | - | - | Stock Options (Right to Buy) | |
| Matthew Buten | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.50 per share. | 03 Oct 2022 | 11,042 | 23,796 | - | 7.5 | 82,815 | Common Shares |
| Matthew Buten | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.37 per share. | 03 Oct 2022 | 11,450 | 34,838 | - | 6.4 | 72,937 | Common Shares |
| Matthew Buten | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.37 per share. | 03 Oct 2022 | 1,550 | 23,388 | - | 6.4 | 9,874 | Common Shares |
| Matthew Buten | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 18,750 | 21,838 | - | 0 | Common Shares | |
| Matthew Buten | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 3,088 | 3,088 | - | 0 | Common Shares | |
| Irina Antonijevic | Director | Other type of transaction at price $ 0.00 per share. | 03 Oct 2022 | 2,535 | 2,535 | - | 0 | Common Shares | |
| Irina Antonijevic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 125,000 | 125,000 | - | - | Stock Options (Right to Buy) | |
| Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 300,000 | 300,000 | - | - | Stock Options (Right to Buy) |